Mary Grecco

Mary Grecco

Articles by Mary Grecco

Mary GreccoESMO TAT 2024 | April 30, 2024
Cancer organoid-based drug sensitivity tests have recently been investigated to predict responses to anticancer drugs.
Read More
Mary GreccoESMO TAT 2024 | April 30, 2024
A study that assessed the impact of miR-29a and miR-143 on gene expression in lung cancer.
Mary GreccoNon-Small Cell Lung Cancer | April 30, 2024
Patient-derived organoids have shown promise in modeling cancer therapy response.
Mary GreccoESMO TAT 2024 | April 25, 2024
A study examined whether AI and clinical knowledge can identify more patients with lung and ovarian cancers.
Mary GreccoESMO TAT 2024 | April 25, 2024
A study detailed the landscape of lung adenocarcinoma progression.
Mary GreccoESMO TAT 2024 | April 25, 2024
MK-1084 as monotherapy and in combination with pembrolizumab is effective in patients with NSCLC.
Mary GreccoNon-Small Cell Lung Cancer | March 28, 2024
A study explored the potential benefits of combining first-generation EGFR-TKI with chemotherapy as neoadjuvant treatment.
Mary GreccoNACLC 2023 | March 26, 2024
Chemotherapy-induced myelosuppression among patients with extensive-stage SCLC is poorly understood.
Mary GreccoNACLC 2023 | March 26, 2024
The VISION study that evaluated pre/post-tepotinib treatment in advanced/metastatic METex14 skipping NSCLC.
Mary GreccoNACLC 2023 | March 26, 2024
The DeLLphi-301 study evaluated patients with advanced SCLC.
Mary GreccoNACLC 2023 | March 25, 2024
Results of a study that evaluated the impact of comprehensive versus limited NGS for advanced NSCLC.
Mary GreccoNACLC 2023 | March 25, 2024
A study evaluated second-line treatment patterns and clinical outcomes of IO in NSCLC.
Mary GreccoNACLC 2023 | March 25, 2024
Patients with metastatic NSCLC who receive first-line anti-PD-L1-based IO may achieve durable disease control.
Mary GreccoNACLC 2023 | March 22, 2024
Lurbinectedin monotherapy is currently being studied in Jazz EMERGE 402 study in patients with metastatic SCLC.
Mary GreccoNACLC 2023 | March 21, 2024
Black and/or socioeconomically disadvantaged patients with advanced NSCLC have higher mortality rates.
Mary GreccoNACLC 2023 | March 21, 2024
Results of a lung screening program found a significantly higher lung cancer prevalence in veterans.
Mary GreccoNACLC 2023 | March 20, 2024
A greater understanding of patients with HER2-mutated NSCLC is critical for developing therapies.
Mary GreccoESMO 2023 | February 28, 2024
A study assessed differences in lung cancer screening eligibility among lung cancer survivors.
Mary GreccoNon-Small Cell Lung Cancer | February 28, 2024
A study analyzed the cost-effectiveness of two different treatment methods in NSCLC.
Mary GreccoESMO 2023 | February 28, 2024
Results of a study explored the potential of automated lung tumor vascularity.